[ <sup>18</sup> F]-Fluorodeoxyglucose (FDG) and Positron Emission Tomography (PET) in Aging and Dementia
John M. HoffmanDepartment of Radiological Sciences, University of California, Los AngelesBarry H. GuzéDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Calif, USAL.R. BaxterDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Calif, USAJ.C. MazziottaDepartment of Neurology;M.E. PhelpsDivision of Nuclear Medicine, Department of Radiological Sciences;
ABI
Аннотация
Alzheimer's disease (AD) is becoming an increasingly important public health problem. The clinical diagnosis of AD continues to be problematic and costly. [18F]-fluorodeoxyglucose-position emission tomography (FDG-PET) can assist with the diagnosis of AD at an early stage. The utility of FDG-PET in AD may also be extremely useful in the future when objective physiologic monitoring of drug effects and therapy are required.
Ҳали таржима қилинмаган
Мавзулар
Идентификаторлар
Иқтибослар ва манбалар
0 та иқтибос0 та фойдаланилган манба